S&P 500   4,589.55 (+0.83%)
DOW   35,680.80 (+0.54%)
QQQ   383.37 (+0.89%)
AAPL   152.51 (+2.46%)
MSFT   323.56 (+0.12%)
FB   316.63 (+1.41%)
GOOGL   2,915.63 (-0.30%)
TSLA   1,068.40 (+2.94%)
AMZN   3,468.80 (+2.25%)
NVDA   247.60 (+1.26%)
BABA   169.79 (+0.33%)
NIO   40.43 (+2.85%)
CGC   13.04 (+2.03%)
GE   104.48 (+0.61%)
AMD   120.97 (-1.07%)
MU   69.43 (+1.74%)
T   25.61 (+2.19%)
F   16.78 (+8.19%)
ACB   6.93 (+1.32%)
DIS   170.00 (+0.27%)
PFE   43.15 (+0.42%)
BA   208.20 (+0.77%)
AMC   35.00 (+0.69%)
S&P 500   4,589.55 (+0.83%)
DOW   35,680.80 (+0.54%)
QQQ   383.37 (+0.89%)
AAPL   152.51 (+2.46%)
MSFT   323.56 (+0.12%)
FB   316.63 (+1.41%)
GOOGL   2,915.63 (-0.30%)
TSLA   1,068.40 (+2.94%)
AMZN   3,468.80 (+2.25%)
NVDA   247.60 (+1.26%)
BABA   169.79 (+0.33%)
NIO   40.43 (+2.85%)
CGC   13.04 (+2.03%)
GE   104.48 (+0.61%)
AMD   120.97 (-1.07%)
MU   69.43 (+1.74%)
T   25.61 (+2.19%)
F   16.78 (+8.19%)
ACB   6.93 (+1.32%)
DIS   170.00 (+0.27%)
PFE   43.15 (+0.42%)
BA   208.20 (+0.77%)
AMC   35.00 (+0.69%)
S&P 500   4,589.55 (+0.83%)
DOW   35,680.80 (+0.54%)
QQQ   383.37 (+0.89%)
AAPL   152.51 (+2.46%)
MSFT   323.56 (+0.12%)
FB   316.63 (+1.41%)
GOOGL   2,915.63 (-0.30%)
TSLA   1,068.40 (+2.94%)
AMZN   3,468.80 (+2.25%)
NVDA   247.60 (+1.26%)
BABA   169.79 (+0.33%)
NIO   40.43 (+2.85%)
CGC   13.04 (+2.03%)
GE   104.48 (+0.61%)
AMD   120.97 (-1.07%)
MU   69.43 (+1.74%)
T   25.61 (+2.19%)
F   16.78 (+8.19%)
ACB   6.93 (+1.32%)
DIS   170.00 (+0.27%)
PFE   43.15 (+0.42%)
BA   208.20 (+0.77%)
AMC   35.00 (+0.69%)
S&P 500   4,589.55 (+0.83%)
DOW   35,680.80 (+0.54%)
QQQ   383.37 (+0.89%)
AAPL   152.51 (+2.46%)
MSFT   323.56 (+0.12%)
FB   316.63 (+1.41%)
GOOGL   2,915.63 (-0.30%)
TSLA   1,068.40 (+2.94%)
AMZN   3,468.80 (+2.25%)
NVDA   247.60 (+1.26%)
BABA   169.79 (+0.33%)
NIO   40.43 (+2.85%)
CGC   13.04 (+2.03%)
GE   104.48 (+0.61%)
AMD   120.97 (-1.07%)
MU   69.43 (+1.74%)
T   25.61 (+2.19%)
F   16.78 (+8.19%)
ACB   6.93 (+1.32%)
DIS   170.00 (+0.27%)
PFE   43.15 (+0.42%)
BA   208.20 (+0.77%)
AMC   35.00 (+0.69%)
NASDAQ:EUCR

Eucrates Biomedical Acquisition Short Interest Ratio and Short Volume

$9.78
0.00 (0.00 %)
(As of 10/28/2021 03:45 AM ET)
Add
Compare
Today's Range
$9.78
$9.78
50-Day Range
$9.65
$9.84
52-Week Range
$9.59
$10.88
Volume
2,000 shs
Average Volume
22,400 shs
Market Capitalization
$131.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A

Eucrates Biomedical Acquisition (NASDAQ:EUCR) Short Interest Data

Current Short Volume
6,300 shares
Previous Short Volume
5,800 shares
Change Vs. Previous Month
+8.62%
Dollar Volume Sold Short
$61,739.37
Short Interest Ratio / Days to Cover
0.7
Last Record Date
October, 15 2021
Outstanding Shares
13,459,000 shares
Float Size
10,790,000 shares
Short Percent of Float
0.06%
Today's Trading Volume
2,000 shares
Average Trading Volume
22,400 shares
Today's Volume Vs. Average
-91.07%
Skip Charts & View Short Interest History

Short Interest Over Time

Days to Cover Over Time

Percentage of Float Shorted Over Time

cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook
Short Selling Eucrates Biomedical Acquisition ?

Sign up to receive the latest short interest report for Eucrates Biomedical Acquisition and its competitors with MarketBeat's FREE newsletter.

Eucrates Biomedical Acquisition (NASDAQ:EUCR) Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
10/15/20216,300 shares $61,739.37 +8.6%0.1%0.7 $9.80
9/30/20215,800 shares $56,724.00 -86.9%0.1%0.8 $9.78
9/15/202144,300 shares $432,811.00 +592.2%0.4%8.7 $9.77
8/31/20216,400 shares $61,952.00 -13.5%0.1%1 $9.68
8/13/20217,400 shares $71,632.00 No Change0.1%1.3 $9.68













Eucrates Biomedical Acquisition (NASDAQ:EUCR) Short Interest Frequently Asked Questions

What is Eucrates Biomedical Acquisition's current short interest?

Short interest is the volume of Eucrates Biomedical Acquisition shares that have been sold short but have not yet been covered or closed out. As of October 15th, traders have sold 6,300 shares of EUCR short. 0.06% of Eucrates Biomedical Acquisition's shares are currently sold short. Learn More on Eucrates Biomedical Acquisition's current short interest.

What is a good short interest ratio for Eucrates Biomedical Acquisition?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. Eucrates Biomedical Acquisition currently has a short interest ratio of 1.0. Learn More on a good short interest ratio for Eucrates Biomedical Acquisition

What is a good short interest percentage for Eucrates Biomedical Acquisition?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.06% of Eucrates Biomedical Acquisition's floating shares are currently sold short.

Is Eucrates Biomedical Acquisition's short interest increasing or decreasing?

Eucrates Biomedical Acquisition saw a increase in short interest during the month of October. As of October 15th, there was short interest totaling 6,300 shares, an increase of 8.6% from the previous total of 5,800 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is Eucrates Biomedical Acquisition's float size?

Eucrates Biomedical Acquisition currently has issued a total of 13,459,000 shares. Some of Eucrates Biomedical Acquisition's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Eucrates Biomedical Acquisition currently has a public float of 10,790,000 shares.

How does Eucrates Biomedical Acquisition's short interest compare to its competitors?

0.06% of Eucrates Biomedical Acquisition's shares are currently sold short. Here is how the short interest of companies in the industry of "holding & other investment offices" compare to Eucrates Biomedical Acquisition: Primavera Capital Acquisition Co. (0.14%), Thunder Bridge Capital Partners III Inc. (0.22%), Motive Capital Corp. (0.13%), FirstMark Horizon Acquisition Corp. (0.00%), M3-Brigade Acquisition II Corp. (0.13%), AltC Acquisition Corp. (0.03%), Equity Distribution Acquisition Corp. (0.06%), Marlin Technology Co. (0.02%), Senior Connect Acquisition Corp. I (0.00%), and African Gold Acquisition Co. (0.04%).

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Advanced Micro Devices, Inc. ($7.75 billion), S&P Global Inc. ($7.73 billion), Charter Communications, Inc. ($5.40 billion), Snowflake Inc. ($4.50 billion), Canadian Pacific Railway Limited ($4.39 billion), Uber Technologies, Inc. ($4.21 billion), Wayfair Inc. ($4.15 billion), Palo Alto Networks, Inc. ($3.27 billion), Teladoc Health, Inc. ($2.78 billion), and DoorDash, Inc. ($2.62 billion). View all of the most shorted stocks.

What does it mean to sell short Eucrates Biomedical Acquisition stock?

Short selling EUCR is an investing strategy that aims to generate trading profit from Eucrates Biomedical Acquisition as its price is falling. To short Eucrates Biomedical Acquisition stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that Eucrates Biomedical Acquisition will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Eucrates Biomedical Acquisition?

A short squeeze for Eucrates Biomedical Acquisition occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of EUCR, which in turn drives the price of the stock up even further.

How often is Eucrates Biomedical Acquisition's short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including EUCR, twice per month. The most recent reporting period available is October, 15 2021.



This page was last updated on 10/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.